ReviewFrontiers in microbiology2022
Epidemiology of extended-spectrum β-lactamases in
Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- High prevalence of ESBL encoding genes in enterobacterales isolated from hospital and environmental wastewater in Pakistan- One Health challenge.Molecular biology reports · 2026Article
- Molecular characterization of extended spectrum beta-lactamase-producing Enterobacterales from urinary tract infections in Burundi.BMC infectious diseases · 2025Article
- Genomic and Phenotypic Insights Into Antibiotic Resistance and Virulence of Klebsiella pneumoniae From the Environment in Southern Taiwan.The Journal of infectious diseases · 2025Article
- First Report of CTX-M-32 and CTX-M-101 inAntibiotics (Basel, Switzerland) · 2025Article
- Threats across boundaries: the spread of ESBL-positiveFrontiers in microbiology · 2025Review
- Extended-Spectrum β-Lactamase-ProducingInfection and drug resistance · 2025Article
- The Impact of COVID-19 Pandemic on ESBL-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Precision bacteriophage therapy for multidrug-resistant recurrent urinary tract infections: From biological rationale to clinical translation in Taiwan.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of antimicrobial resistance among microorganisms is a serious public health concern, and extended-spectrum β-lactamases (ESBL)-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.